Timothy P. Walbert - 28 Jul 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Role
Chairman, President and CEO, Director
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol
HZNP
Transactions as of
28 Jul 2021
Transactions value $
-$4,125,269
Form type
4
Filing time
30 Jul 2021, 16:28:57 UTC
Previous filing
02 Jul 2021
Next filing
27 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Gift $0 -5K -0.59% $0.00 846K 08 Jul 2021 Direct
transaction HZNP Ordinary Shares Award $0 +34.8K +4.12% $0.00 881K 28 Jul 2021 Direct F1
transaction HZNP Ordinary Shares Tax liability -$1.58M -15.4K -1.75% $102.50 865K 28 Jul 2021 Direct
transaction HZNP Ordinary Shares Sale -$2.29M -22.6K -2.61% $101.65 843K 30 Jul 2021 Direct F2, F3
transaction HZNP Ordinary Shares Sale -$250K -2.43K -0.29% $102.57 840K 30 Jul 2021 Direct F2, F4
holding HZNP Ordinary Shares 21K 28 Jul 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Performance Restricted Stock Units (PSUs) Award $0 +69.7K $0.00 69.7K 28 Jul 2021 Ordinary Shares 69.7K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.09 to $102.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.33 to $102.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Each PSU represents a contingent right to receive one ordinary share of the Issuer.